The burden of severely drug-refractory epilepsy : a comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using German health insurance data

  • Purpose: To evaluate long-term outcome of three years and treatment patterns of patients suffering from severely drug-refractory epilepsy (SDRE). Methods: This analysis was population-based and retrospective, with data collected from four million individuals insured by statutory German health insurance. ICD-10 codes for epilepsy (G40*) and intake of anticonvulsants were used to identify prevalent cases, which were then compared with a matched cohort drawn from the population at large. Insurance data were available from 2008 to 2013. Any patient who had been prescribed with at least four different antiepileptic drugs (AEDs) in an 18-month period was defined as an SDRE case. Results: A total of 769 patients with SDRE were identified. Of these, 19% were children and adolescents; the overall mean age was 42.3 years, 45.4% were female and 54.6% male. An average of 2.7 AEDs per patient was prescribed during the first follow-up year. The AEDs most commonly prescribed were: levetiracetam (53.5%), lamotrigine (41.4%), valproate (41.3%), lacosamide (20.4%), and topiramate (17.8%). During 3-year follow-up, there was an annual rate of hospitalization in the range 42.7 to 55%, which was significantly higher than the 11.6–12.8% (p < 0.001) for the matched controls. Admissions to hospital because of epilepsy ranged between 1.7 and 1.9 per year, with an average duration for each epilepsy-caused hospitalization of 10–11.1 days. The number of comorbidities for SDRE patients was significantly increased compared with the matched controls: depression (28% against 10%), vascular disorders (22% against 5%), and injury rates were also higher (head 16% against 3%, trunk and limbs 16% against 8%). The 3-year mortality rate for SDRE patients was 14% against 2.1% in the matched cohort. Conclusion: SDRE patients are treated with AED polytherapy for all of the 3-year follow-up period. They are hospitalized more frequently than the general population and show increased morbidity levels and a sevenfold increase in mortality rate over 3 years. Further examination is required of ways in which new approaches to treatment could lead to better outcomes in severely affected patients.

Download full text files

Export metadata

Metadaten
Author:Adam StrzelczykORCiDGND, Claudia Griebel, Wolfram Lux, Felix RosenowORCiDGND, Jens-Peter Reese
URN:urn:nbn:de:hebis:30:3-453425
DOI:https://doi.org/10.3389/fneur.2017.00712
ISSN:1664-2295
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/29312132
Parent Title (English):Frontiers in neurology
Publisher:Frontiers Research Foundation
Place of publication:Lausanne
Contributor(s):Antonio Gil-Nagel
Document Type:Article
Language:English
Year of Completion:2017
Date of first Publication:2017/12/22
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2018/01/16
Tag:epidemiology; morbidity; population-based; secondary data analysis; seizure
Volume:8
Issue:Art. 712
Page Number:10
First Page:1
Last Page:10
Note:
Copyright: © 2017 Strzelczyk, Griebel, Lux, Rosenow and Reese. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
HeBIS-PPN:426726006
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0